19 Jun Gavreto (pralsetininb) DHCPL- Removal from the Pharmaceutical Market
Posted at 09:46h
in
The DHCP letter initiated by Roche is intended to inform healthcare professionals about deregistration of approved indications for Gavreto® (pralsetinib) and removal from the South African pharmaceutical market.
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
19/06/2024
File Type:
pdf
Category:
Communication To Health Care Professionals